An update on PTEN modulators – a patent review

References

• Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998;273(22):13375–13378.
   PubMed Web of Science ®Google Scholar
• Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012;13(5):283–296.
   PubMed Web of Science ®Google Scholar
• Lee YR, Chen M, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor: new modes and prospects. Nat Rev Mol Cell Biol. 2018;19(9):547–562.
   PubMed Web of Science ®Google Scholar
• Boosani CS, Agrawal DK. PTEN modulators: a patent review. Expert Opin Ther Pat. 2013;23(5):569–580.
   PubMed Web of Science ®Google Scholar
• Milella M, Falcone I, Conciatori F, et al. PTEN: multiple functions in human malignant tumors. Front Oncol. 2015;5:24.
   PubMed Web of Science ®Google Scholar
• van Diepen MT, Parsons M, Downes CP, et al. MyosinV controls PTEN function and neuronal cell size. Nat Cell Biol. 2009;11(10):1191–1196.
   PubMed Web of Science ®Google Scholar
• Gomes AM, Soares MV, Ribeiro P, et al. Adult B-cell acute lymphoblastic leukemia cells display decreased PTEN activity and constitutive hyperactivation of PI3K/Akt pathway despite high PTEN protein levels. Haematologica. 2014;99(6):1062–1068.
   PubMed Web of Science ®Google Scholar
• Trotman LC, Wang X, Alimonti A, et al. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell. 2007;128(1):141–156.
   PubMed Web of Science ®Google Scholar
• Vazquez F, Grossman SR, Takahashi Y, et al. Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex. J Biol Chem. 2001;276(52):48627–48630.
   PubMed Web of Science ®Google Scholar
• Vazquez F, Ramaswamy S, Nakamura N, et al. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000;20(14):5010–5018.
   PubMed Web of Science ®Google Scholar
• Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001;276(2):993–998.
   PubMed Web of Science ®Google Scholar
• Park KK, Liu K, Hu Y, et al. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science (New York, NY). 2008;322(5903):963–966.
   Google Scholar
• O’Donovan KJ, Ma K, Guo H, et al. B-RAF kinase drives developmental axon growth and promotes axon regeneration in the injured mature CNS. J Exp Med. 2014;211(5):801–814.
   PubMed Web of Science ®Google Scholar
• de Lima S, Habboub G, Benowitz LI. Combinatorial therapy stimulates long-distance regeneration, target reinnervation, and partial recovery of vision after optic nerve injury in mice. Int Rev Neurobiol. 2012;106:153–172.
   PubMed Web of Science ®Google Scholar
• de Lima S, Koriyama Y, Kurimoto T, et al. Full-length axon regeneration in the adult mouse optic nerve and partial recovery of simple visual behaviors. Proc Natl Acad Sci U S A. 2012;109(23):9149–9154.
   PubMed Web of Science ®Google Scholar
• Kurimoto T, Yin Y, Omura K, et al. Long-distance axon regeneration in the mature optic nerve: contributions of oncomodulin, cAMP, and pten gene deletion. J Neurosci. 2010;30(46):15654–15663.
   PubMed Web of Science ®Google Scholar
• Leibinger M, Andreadaki A, Fischer D. Role of mTOR in neuroprotection and axon regeneration after inflammatory stimulation. Neurobiol Dis. 2012;46(2):314–324.
   PubMed Web of Science ®Google Scholar
• Sun F, Park KK, Belin S, et al. Sustained axon regeneration induced by co-deletion of PTEN and SOCS3. Nature. 2011;480(7377):372–375.
   PubMed Web of Science ®Google Scholar
• Gallaher ZR, Steward O. Modest enhancement of sensory axon regeneration in the sciatic nerve with conditional co-deletion of PTEN and SOCS3 in the dorsal root ganglia of adult mice. Exp Neurol. 2018;303:120–133.
   PubMed Web of Science ®Google Scholar
• Mak LH, Vilar R, Woscholski R. Characterisation of the PTEN inhibitor VO-OHpic. J Chem Biol. 2010;3(4):157–163.
   PubMedGoogle Scholar
• Rosivatz E, Matthews JG, McDonald NQ, et al. A small molecule inhibitor for phosphatase and tensin homologue deleted on chromosome 10 (PTEN). ACS Chem Biol. 2006;1(12):780–790.
   PubMed Web of Science ®Google Scholar
• Schmid AC, Byrne RD, Vilar R, et al. Bisperoxovanadium compounds are potent PTEN inhibitors. FEBS Lett. 2004;566(1–3):35–38.
   PubMed Web of Science ®Google Scholar
• Zhang ZF, Chen J, Han X, et al. Bisperoxovandium (pyridin-2-squaramide) targets both PTEN and ERK1/2 to confer neuroprotection. Br J Pharmacol. 2017;174(8):641–656.
   PubMed Web of Science ®Google Scholar
• Christie KJ, Webber CA, Martinez JA, et al. PTEN inhibition to facilitate intrinsic regenerative outgrowth of adult peripheral axons. J Neurosci. 2010;30(27):9306–9315.
   PubMed Web of Science ®Google Scholar
• Walker CL, Walker MJ, Liu NK, et al. Systemic bisperoxovanadium activates Akt/mTOR, reduces autophagy, and enhances recovery following cervical spinal cord injury. PloS One. 2012;7(1):e30012.
   PubMed Web of Science ®Google Scholar
• Walker CL, Xu XM. PTEN inhibitor bisperoxovanadium protects oligodendrocytes and myelin and prevents neuronal atrophy in adult rats following cervical hemicontusive spinal cord injury. Neurosci Lett. 2014;573:64–68.
   PubMed Web of Science ®Google Scholar
• Zhao J, Qu Y, Wu J, et al. PTEN inhibition prevents rat cortical neuron injury after hypoxia-ischemia. Neuroscience. 2013;238:242–251.
   PubMed Web of Science ®Google Scholar
• Li S. InventorPten antagonist peptides and methods of using the same. US patent US10011638B2. 2016.
   Google Scholar
• Lee KH, Noh MJ, Ahn K. InventorsTreatment of damaged nerve with pten inhibitor. US patent WO2015066701A1. 2016.
   Google Scholar
• Boosani CS, Nalabothula N, Munugalavadla V, et al. FAK and p38-MAP kinase-dependent activation of apoptosis and caspase-3 in retinal endothelial cells by alpha1(IV)NC1. Invest Ophthalmol Vis Sci. 2009;50(10):4567–4575.
   PubMed Web of Science ®Google Scholar
• Boosani CS, Nalabothula N, Sheibani N, et al. Inhibitory effects of arresten on bFGF-induced proliferation, migration, and matrix metalloproteinase-2 activation in mouse retinal endothelial cells. Curr Eye Res. 2010;35(1):45–55.
   PubMed Web of Science ®Google Scholar
• Vavvas D, Miller JW, Takeuchi K. InventorsTreating ocular neovascularization. US patent US10143703B2. 2017.
   Google Scholar
• Theodoropoulou S, Kolovou PE, Morizane Y, et al. Retinoblastoma cells are inhibited by aminoimidazole carboxamide ribonucleotide (AICAR) partially through activation of AMP-dependent kinase. Faseb J. 2010;24(8):2620–2630.
   PubMed Web of Science ®Google Scholar
• Webb T, Wang Z. InventorsCompositions and methods of making expanded hematopoietic stem cells using pten inhibitors. US patent WO2018217567A1. 2018.
   Google Scholar
• Yue F, Bi P, Wang C, et al. Pten is necessary for the quiescence and maintenance of adult muscle stem cells. Nat Commun. 2017;8:14328.
   PubMed Web of Science ®Google Scholar
• Duan S, Yuan G, Liu X, et al. PTEN deficiency reprogrammes human neural stem cells towards a glioblastoma stem cell-like phenotype. Nat Commun. 2015;6:10068.
   PubMed Web of Science ®Google Scholar
• Zhang G, Wang W, Yao C, et al. Radiation-resistant cancer stem-like cell properties are regulated by PTEN through the activity of nuclear beta-catenin in nasopharyngeal carcinoma. Oncotarget. 2017;8(43):74661–74672.
   PubMedGoogle Scholar
• Yilmaz OH, Valdez R, Theisen BK, et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature. 2006;441(7092):475–482.
   PubMed Web of Science ®Google Scholar
• Schubbert S, Jiao J, Ruscetti M, et al. Methods for PTEN in stem cells and cancer stem cells. Methods Mol Biol. 2016;1388:233–285.
   PubMedGoogle Scholar
• Qin G, Xie J, Chen L, et al. PTEN inhibition preserves trigeminal nucleus caudalis neuron activation through tyrosine phosphorylation of the NR2B subunit at Tyr1472 of the NMDA receptor in a rat model of recurrent migraine. Neurol Res. 2016;38(4):320–326.
   PubMed Web of Science ®Google Scholar
• Huang SY, Sung CS, Chen WF, et al. Involvement of phosphatase and tensin homolog deleted from chromosome 10 in rodent model of neuropathic pain. J Neuroinflammation. 2015;12:59.
   PubMed Web of Science ®Google Scholar
• Wen Z-H, Tai M-H, Huang S-Y, et al. InventorsMethod for treating pain and method for screening pharmaceutical compositions having an anti-pain effect. TW patent US9999658B2. 2018.
   Google Scholar
• Pulido R. PTEN inhibition in human disease therapy. Molecules. 2018;23(2). DOI:10.3390/molecules23020285
   Web of Science ®Google Scholar
• Dave VG, Cai J. InventorsPten binding compounds, formulations, and uses thereof. US patent WO2018151835A1. 2018.
   Google Scholar
• Li H, Wang P, Sun Q, et al. Following cytochrome c release, autophagy is inhibited during chemotherapy-induced apoptosis by caspase 8-mediated cleavage of Beclin 1. Cancer Res. 2011;71(10):3625–3634.
   PubMed Web of Science ®Google Scholar
• Petit A, Kawarai T, Paitel E, et al. Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations. J Biol Chem. 2005;280(40):34025–34032.
   PubMed Web of Science ®Google Scholar
• Reggiori F, Tucker KA, Stromhaug PE, et al. The Atg1-Atg13 complex regulates Atg9 and Atg23 retrieval transport from the pre-autophagosomal structure. Dev Cell. 2004;6(1):79–90.
   PubMed Web of Science ®Google Scholar
• Woon KD, Eun-hee C, Min-hee L, et al. InventorsComposition for diagnosing neuropathic pain comprising PTEN-induced putative kinase 1. KR patent KR101847608B1. 2018.
   Google Scholar
• Jo M, Imsang S, Lee SY, et al. InventorsComposition for treatment or prevention of autoimmune diseases comprising PTEN-induced kinase 1 protein or nucleotide. KR patent KR 101712695B1. 2017.
   Google Scholar
• Vali S, Usmani S, Sultana Z, et al. InventorsCombination of nelfinavir, metformin and rosuvastatin for treating cancer caused by aberrations in pten/tp53. US patent US10098880B2. 2017.
   Google Scholar
• Kaur B. InventorExpression of pten-long with ocolytic viruses. US patent WO2018023114A1. 2018.
   Google Scholar
• Jean S, Kiger AA. Classes of phosphoinositide 3-kinases at a glance. J Cell Sci. 2014;127(Pt 5):923–928.
   PubMed Web of Science ®Google Scholar
• Stern HM, Kutok JL. Inventorstreatment of cancers using PI3 kinase isoform modulators. US patent US20140377258A1. 2014.
   Google Scholar
• Kim TW, Jin DH, Hong SW, et al. InventorsComposition for treatment or metastasis suppression of cancers which includes p34 expression inhibitor or activity inhibitor as active ingredient. KR patent US9752151B2. 2017.
   Google Scholar
• Mathur D, Stratikopoulos E, Ozturk S, et al. PTEN regulates glutamine flux to pyrimidine synthesis and sensitivity to dihydroorotate dehydrogenase inhibition. Cancer Discov. 2017;7(4):380–390.
   PubMed Web of Science ®Google Scholar
• Parsons R, Mathur D, Stratikopoulos I. InventorsMethods for treating pten-mutant tumors. US patent WO2018038886A1. 2018.
   Google Scholar
• Munn D, Mellor A. InventorsMethods and compositions for treating cancer. US patent WO2017004167A1. 2017.
   Google Scholar
• Lee Y-M, Oh SY. InventorsPharmaceutical composition comprising MicroRNA-30B, MicroRNA-133A, or MicroRNA-202-5P inhibitor for inhibiting cancer. KR patent US9295709B2. 2016.
   Google Scholar
• Wickstrom E, Jin YY, Wickstrom E, et al. InventorsCompositions and methods of using microrna inhibitors. US patent WO2015123449A2. 2015.
   Google Scholar